Danish drug manufacturer Novo Nordisk revealed that results of its diabetes therapy insulin, degludec, has shown to reduce blood sugar levels and could pose a threat to the popular drug Lantus, manufactured by Sanofi.
The results of the trial was presented at the European Association for the Study of Diabetes meeting with investigators revealing that the drug also reduced glycated haemoglobin levels with similar rates of hypoglycaemia when compared to Lantus.
In this study, haemoglobin A1C levels were reduced by 1.28 percentage points at 26-weeks to 7.2% with insulin degludec. This result is similar to the reductions produced by Lantus, which is the biggest-selling insulin product in the world.
Announcing the results of the study, lead investigator Professor Stephen Atkin said, "This study demonstrates that with insulin degludec glycemic control can be maintained even if people unintentionally delay a dose or take their insulin at a different time of the day."